The men's health optimization movement is overwhelmingly marketed to 35-to-55-year-olds. That leaves men over 60 in an awkward position: clearly eligible for hormonal and metabolic support but underserved by an industry that assumes its audience is two decades younger. The therapies work at 60+ — but the protocols, monitoring, and risk-benefit calculations require adjustment.
What the Evidence Supports After 60
Testosterone Replacement
The Testosterone Trials (TTrials), published in 2016–2018, specifically studied men over 65 with documented low testosterone. The results showed meaningful benefits in sexual function, physical function, bone density, and anemia — but not in cognitive function or vitality. The TRAVERSE trial (2023) confirmed cardiovascular safety in men 45–80, including the 60+ subgroup.
TRT after 60 is evidence-based — but the approach differs:
- Lower target ranges: Targeting 400–600 ng/dL total T rather than the 600–900 range common in younger men. Age-related receptor sensitivity changes mean lower levels may produce adequate clinical response.
- Conservative dosing: Starting at lower doses (80–100mg/week testosterone cypionate) and titrating gradually. Polycythemia risk increases with age.
- More frequent monitoring: Hematocrit, PSA, and metabolic panels every 3 months in the first year, then every 6 months once stable.
- Bone density benefit: TRT in older men consistently improves bone mineral density. For men with osteopenia or osteoporosis (underdiagnosed in men), TRT addresses a real risk.
GLP-1 Medications
Obesity in older adults carries unique risks: sarcopenia (muscle loss), falls, and bone density loss alongside the standard metabolic concerns. GLP-1 medications produce significant weight loss at any age, but in men over 60, preserving lean mass during weight loss is critical.
The approach: GLP-1 therapy in older men should always be paired with resistance exercise and adequate protein intake (1.2–1.6g/kg/day). Weight loss without muscle preservation accelerates frailty. Monitoring should include DEXA for lean mass and bone density, not just scale weight.
ED Treatment
PDE5 inhibitors are safe and effective after 60 — the pivotal trials included men up to age 80+. The main adjustments: start at lower doses (sildenafil 25mg, tadalafil 5mg), monitor blood pressure more closely (particularly with antihypertensive combinations), and address underlying vascular disease as the root cause rather than treating ED in isolation.
What Requires Extra Caution
Peptides and Add-Ons
The evidence for peptides like sermorelin and NAD+ injections is thin at any age — and thinner for older adults specifically. The physiological reserve for handling additional pharmacological interventions narrows with age. Drug interactions become more likely with the larger medication lists common after 60 (antihypertensives, statins, anticoagulants, proton pump inhibitors).
The conservative approach: limit the stack to evidence-backed core therapies (TRT, GLP-1, ED medication) and add peptides only if specific, measurable goals justify the additional pharmacological exposure.
The 60+ Protocol Framework
Conservative Enhancement Principles
- Start low, go slow: Lower starting doses, longer titration intervals, tighter monitoring
- Fewer medications, better managed: Prioritize 2–3 evidence-backed therapies over a 5-medication stack
- Preserve muscle: Every weight-loss intervention must include resistance training and protein targets
- Monitor more: Bloodwork every 3 months until stable; PSA every 6 months on TRT
- Coordinate with your PCP: At 60+, the likelihood of additional health conditions (cardiovascular, metabolic, renal) makes PCP coordination essential, not optional
The Bottom Line
Optimization Doesn't Stop at 60 — But It Changes Character
Men over 60 can benefit meaningfully from TRT, GLP-1 therapy, and ED treatment. The evidence supports it. The approach just needs to be more conservative — lower targets, more monitoring, fewer add-ons, and genuine coordination with primary care. The goal is functional quality of life, not the supraphysiological optimization that 35-year-old influencers chase.